Tag Archives: CEO

Christi Shaw to Depart Gilead and Kite Leadership

On Friday, February 17, Gilead / Kite announced (press release) that Christi Shaw (Kite’s CEO) decided to depart by the end of Q1 2023. Below, Celltelligence provides insights on Shaw’s tenure in Kite, while discussing the profile of her potential replacement.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision Appoints Michael Amoroso as Their New CEO

On Monday, September 27, Precision BioSciences announced (press release) the appointment of Michael Amoroso as the company’s President, Chief Executive Officer (CEO), and member of the Board of Directors, all effective October 15, 2021. Below, Celltelligence provides insights on how Amoroso could lead Precision through their next phase of growth.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Ziopharm Appoints Kevin Boyle as Their New CEO

On Monday, August 30, Ziopharm announced (press release / webcast) the appointment of Kevin Boyle as their new CEO, with Heidi Hagen (interim CEO) returning to her position on the Board of Directors. Below, Celltelligence provides insights on how Boyle could help improve Ziopharm’s financial situation while regaining shareholders’ confidence.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Overland Appoints Shuyuan Yao as CEO

On Monday, June 21, Allogene announced (press release) that Shuyuan Yao has been appointed as CEO of Allogene Overland Biopharm. Below, Celltelligence provides insights on how Shuyuan Yao’s vast cell therapy experience could position Allogene Overland for rapid growth in Greater China and throughout the Asia-Pacific region.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.